Follow The Filings

MEDP Medpace Holdings Inc.

Health Care, filed as MEDPACE HLDGS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 2 managers in 2026 Q2

  • 4 Owners
  • Max 4.5%
  • $283M
  • 2 reduce 2 small

In 2026 Q2 Vulcan Value Partners and Terry Smith trimmed Medpace.

Who owns this now

Largest portfolio weights among holders, up to 4.5% (Francois Rochon, Giverny Capital). Not free-float ownership.

  1. Francois Rochon Reduce 4.5%
  2. Vulcan Value Partners Reduce 2.3%
  3. Mairs & Power Add 0.42%
  4. Terry Smith Reduce 0.20%

Who owns MEDP

Sorted by value, long equity only, as of 2026 Q2.

History
Francois Rochon, Giverny Capital 4.5% Small trim −0.8% 253,931 $134M History
Vulcan Value Partners 2.3%, was 2.6% Reduce −30.2% 141,743 $75M History
Mairs & Power 0.42% Small add +1.2% 86,715 $46M History
Terry Smith, Fundsmith 0.20%, was 0.23% Reduce −16.4% 52,372 $28M History

4 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by MEDP's executives, directors and 10% owners in the last 12 months, from their Form 4s

All MEDP insider trades
  • None no insider bought on the open market
  • $440M sold by 9 insiders outside a trading plan
  • $12.8M sold by 1 insider under 10b5-1 plans
  1. Susan E Burwig Exec. VP, Operations
    Sale
    $13.5M 20,000 shares at $677.00 27% of stake
    Traded Oct 26–27 Filed Oct 28
    ↗
  2. August J. Troendle CEO
    Sale
    $30.3M 48,667 shares at $623.03 13% of stake
    Traded Sep 29–30 Filed Oct 1
    ↗
  3. August J. Troendle CEO
    Sale
    $1.6M 2,564 shares at $620.10 0.7% of stake
    Traded Sep 25–28 Filed Sep 29
    ↗
  4. August J. Troendle CEO
    Sale
    $27.4M 43,916 shares at $624.01 10% of stake
    Traded Sep 23–24 Filed Sep 25
    ↗
  5. August J. Troendle CEO
    Sale
    $44.4M 70,901 shares at $626.62 14% of stake
    Traded Sep 21–22 Filed Sep 23
    ↗
  6. August J. Troendle CEO
    Sale
    $6.7M 10,880 shares at $620.40 2.1% of stake
    Traded Sep 17 Filed Sep 21
    ↗
  7. August J. Troendle CEO
    Sale
    $15.4M 24,741 shares at $621.00 4.6% of stake
    Traded Sep 15–16 Filed Sep 17
    ↗
  8. August J. Troendle CEO
    Sale
    $403K 650 shares at $620.27 0.1% of stake
    Traded Aug 27 Filed Aug 31
    ↗
  9. Robert O. Kraft Director
    Sale
    $2.4M 3,858 shares at $617.81 80% of stake
    Traded Aug 26 Filed Aug 28
    ↗
  10. August J. Troendle CEO
    Sale
    $2.9M 4,673 shares at $620.08 0.9% of stake
    Traded Aug 25–26 Filed Aug 27
    ↗
  11. August J. Troendle CEO
    Sale
    $10M 15,978 shares at $623.93 2.8% of stake
    Traded Aug 21–24 Filed Aug 25
    ↗
  12. Kevin M. Brady CFO
    Sale
    $2.1M 3,400 shares at $625.24 21% of stake
    Traded Aug 20 Filed Aug 24
    ↗
  13. August J. Troendle CEO
    Sale
    $26.3M 42,783 shares at $614.30 7.1% of stake
    Traded Aug 19–20 Filed Aug 21
    ↗
  14. Brian T Carley Director
    Sale
    $3M 5,000 shares at $608.63 15% of stake
    Traded Aug 19 Filed Aug 21
    ↗
  15. Fred B Davenport Jr. Director
    Sale
    $4.4M 7,283 shares at $606.15 66% of stake
    Traded Aug 19 Filed Aug 21
    ↗

Also filed in the last 12 months, not counted as buying or selling: 35 option exercises and 1 gift.

Congress

6 members of Congress traded MEDP in the last three years: 6 buys and 10 sales. 2 members listed it in 2025 annual reports.

All Congress trades
  1. David J. Taylor R-OH-2 Buy $1K–$15K May 15 filed May 28
  2. David J. Taylor R-OH-2 Buy $1K–$15K May 15 filed May 28
  3. David J. Taylor R-OH-2 Buy $1K–$15K Feb 26 filed Mar 6
  4. Gilbert Ray Cisneros, Jr. D-CA-31 Sell $15K–$50K Jan 15 filed Feb 13
  5. David J. Taylor R-OH-2 Buy $1K–$15K Jan 29 filed Feb 2
  6. David J. Taylor R-OH-2 Sell $1K–$15K Jan 16 filed Feb 2

SEC filings

Recent issuer filings from EDGAR, 8 shown.

Filed Form Detail Links
10-Q Filing Doc
8-K 2.02,8.01,9.01 Filing Doc
SCHEDULE 13D/A — Filing Doc
SCHEDULE 13G — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.02 Filing Doc
8-K 5.03,5.07,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 3 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $1.89B $2.11B $2.53B
Net income $282.81M $404.39M $451.12M
Net margin * 15.0% 19.2% 17.8%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $0.594B $1.03B $0.99B
Total non-current assets * $1.06B $1.07B $0.986B
Total assets $1.66B $2.1B $1.98B
Total current liabilities $0.925B $1.1B $1.34B
Total non-current liabilities * $172.75M $170.77M $172.65M
Total equity $558.95M $825.54M $459.07M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $433.37M $608.82M $713.22M
Cash from investing -$34.63M -$28.31M -$31.14M
Cash from financing -$182.64M -$154.01M -$860.39M
Net change in cash $217.18M $423.99M -$172.39M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.